Oxford Biomedica offers comprehensive analytical services for gene therapy products. Their in-house QC labs ensure full vector characterization, quality control, and stability testing, supporting clinical and commercial supply with advanced assays and regulatory expertise.

Oxford Biomedica's LentiVector™ platform is the first commercially approved lentiviral-based gene delivery system. It offers optimized processes for higher drug substance yields, superior quality, and reliable commercial manufacturing, supporting FDA-approved therapies.

Oxford Biomedica ensures the highest product quality and regulatory compliance for gene therapy. Their experienced team supports successful regulatory filings, risk mitigation, and constructive relationships with authorities, ensuring smooth approval processes for their partners.

Oxford Biomedica's process development services optimize yield and quality, reducing time and costs for clinical trials. Their serum-free, animal component-free processes enhance productivity, ensuring robust, reproducible, and commercially viable solutions for gene and cell therapy.

Oxford Biomedica's manufacturing services offer end-to-end viral vector production with rigorous GMP processes. Their state-of-the-art facilities ensure high-quality, scalable solutions for gene therapy, supporting clinical and commercial needs efficiently.

Oxford Biomedica's AAV platform, inAAVate™, provides advanced solutions for gene therapy. It focuses on high-quality, scalable manufacturing processes to ensure efficient and reliable production of adeno-associated virus vectors for clinical and commercial use.